149 related articles for article (PubMed ID: 36734254)
21. Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.
Elliott A; Zhang J; Zhang Q; Swensen J; Martin D; Xiu J; Geynisman DM; Vaena D; Herzog TJ; Holloway RW; El-Deiry WS; Spetzler D; Heath E; Stafford P; Korn WM
J Mol Diagn; 2021 Dec; 23(12):1761-1773. PubMed ID: 34562615
[TBL] [Abstract][Full Text] [Related]
22. The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review.
Chen Q; Zhong T
Drug Des Devel Ther; 2015; 9():5115-22. PubMed ID: 26379424
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis.
Meng L; Yang Y; Hu X; Zhang R; Li X
J Transl Med; 2023 Feb; 21(1):79. PubMed ID: 36739407
[TBL] [Abstract][Full Text] [Related]
24. Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis.
Cao J; Zhu X; Zhao X; Li XF; Xu R
PLoS One; 2016; 11(7):e0158770. PubMed ID: 27368058
[TBL] [Abstract][Full Text] [Related]
25. Current progress and novel strategies that target CDK12 for drug discovery.
Lei P; Zhang J; Liao P; Ren C; Wang J; Wang Y
Eur J Med Chem; 2022 Oct; 240():114603. PubMed ID: 35868123
[TBL] [Abstract][Full Text] [Related]
26. CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3.
Zhong K; Luo W; Li N; Tan X; Li Y; Yin S; Huang Y; Fang L; Ma W; Cai Y; Yin Y
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38186306
[TBL] [Abstract][Full Text] [Related]
27. Prognostic role of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer: A meta-analysis of results from multivariate analysis.
Guo J; Fang J; Huang X; Liu Y; Yuan Y; Zhang X; Zou C; Xiao K; Wang J
Int J Surg; 2018 Dec; 60():216-223. PubMed ID: 30468905
[TBL] [Abstract][Full Text] [Related]
28. The association between sexual dysfunction and prostate cancer: a systematic review and meta-analysis.
Dilixiati D; Kadier K; Laihaiti D; Lu JD; Azhati B; Rexiati M
J Sex Med; 2023 Feb; 20(2):184-193. PubMed ID: 36763951
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of pretreatment systemic immune-inflammation index in patients with prostate cancer: a meta-analysis.
Zhang B; Xu T
World J Surg Oncol; 2023 Jan; 21(1):2. PubMed ID: 36600256
[TBL] [Abstract][Full Text] [Related]
30.
Antonarakis ES; Isaacsson Velho P; Fu W; Wang H; Agarwal N; Sacristan Santos V; Maughan BL; Pili R; Adra N; Sternberg CN; Vlachostergios PJ; Tagawa ST; Bryce AH; McNatty AL; Reichert ZR; Dreicer R; Sartor O; Lotan TL; Hussain M
JCO Precis Oncol; 2020; 4():370-381. PubMed ID: 32462107
[TBL] [Abstract][Full Text] [Related]
31. In Reply to "Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer".
Valle LF; Nickols NG; Yamoah K; Garraway IP; Maxwell KN; Lynch JA
Oncologist; 2023 Nov; 28(11):e1129-e1130. PubMed ID: 37706534
[TBL] [Abstract][Full Text] [Related]
32. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
Shen H; Liu J; Sun G; Yan L; Li Q; Wang Z; Xie L
Aging (Albany NY); 2020 Dec; 13(2):2279-2293. PubMed ID: 33318295
[TBL] [Abstract][Full Text] [Related]
33. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
34. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
Kwon DH; Chou J; Yip SM; Reimers MA; Zhang L; Wright F; Dhawan MS; Borno HT; Desai A; Aggarwal RR; Wyatt AW; Small EJ; Alva AS; Chi KN; Feng FY; Koshkin VS
Cancer; 2021 Jun; 127(12):1965-1973. PubMed ID: 33690902
[TBL] [Abstract][Full Text] [Related]
35. The clinical prognostic value of lncRNA LINC00675 in cancer patients: A meta-analysis.
Hua H; Wang J; Zhong P; Mou T; Liu P; Xie F
Medicine (Baltimore); 2021 Apr; 100(16):e25244. PubMed ID: 33879657
[TBL] [Abstract][Full Text] [Related]
36. MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer.
Zeng Z; He W; Jiang Y; Jiang H; Cheng X; Deng W; Zhou X; Zhang C; Wang G
BMC Cancer; 2022 Nov; 22(1):1162. PubMed ID: 36357836
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological and prognostic significance of osteopontin expression in patients with prostate cancer: a systematic review and meta-analysis.
Yu A; Guo K; Qin Q; Xing C; Zu X
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 33635319
[TBL] [Abstract][Full Text] [Related]
38. A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype.
Qian K; Wang G; Ju L; Liu J; Luo Y; Wang Y; Peng T; Chen F; Zhang Y; Xiao Y; Wang X
Oncogene; 2020 Oct; 39(44):6871-6878. PubMed ID: 32978518
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of preoperative lymphocyte-related systemic inflammatory biomarkers in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: a systematic review and meta-analysis.
Shao Y; Li W; Wang D; Wu B
World J Surg Oncol; 2020 Oct; 18(1):273. PubMed ID: 33097052
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.
Tang L; Li X; Wang B; Luo G; Gu L; Chen L; Liu K; Gao Y; Zhang X
PLoS One; 2016; 11(4):e0153981. PubMed ID: 27096158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
